Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.34 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079065 | 1.00 | DRD1 (0.40) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL23927010 | 0.92 | DRD1 (0.40) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL30079139 | 0.92 | DRD1 (0.40) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL23927076 | 0.89 | TNKS (0.36) | DRD1TNKSMMP13BCAT2BCAT1 | |
| SCHEMBL30079079 | 0.88 | HSD17B10 (0.43) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL23926980 | 0.88 | HSD17B10 (0.43) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL23927050 | 0.87 | DRD1 (0.39) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL25027659 | 0.87 | TNKS (0.38) | DRD1TNKSKDM4EALDH1A1HPGD | |
| SCHEMBL23926975 | 0.87 | TNKS (0.38) | DRD1TNKSKDM4EHAVCR2HRH3 | |
| SCHEMBL30079057 | 0.87 | TNKS (0.38) | DRD1TNKSKDM4EHAVCR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | claimed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | claimed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | claimed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | claimed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | DRD1 333/4885TNKS 4456/4885KDM4E 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.